Pioglitazone may lower plaque inflammation in type 2 diabetes

10/12/2011 | MedPage Today (free registration)

Patients with carotid atherosclerosis and type 2 diabetes or impaired glucose tolerance who took 15 to 30 milligrams of pioglitazone for four months attained similar fasting plasma glucose levels as those who took glimepiride, but showed significant improvements in atherosclerotic plaque inflammation compared with the glimepiride-treated group, according to a study in JACC: Cardiovascular Imaging. Researchers found that patients who took pioglitazone had increased levels of high-density lipoprotein, which may have helped to suppress atherosclerotic plaque.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations